{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:23:46Z","timestamp":1788272626185,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.neuropharm.2020.107989","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T19:17:48Z","timestamp":1580843868000},"page":"107989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model"],"prefix":"10.1016","volume":"167","author":[{"given":"Siwon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambily Nath","family":"Indu Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.Yeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini M.","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Ko","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeick","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayoung","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ae Nim","family":"Pae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Duk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.107989_bib1","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1523\/JNEUROSCI.0426-16.2016","article-title":"Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental Parkinson\u2019s-like disease","volume":"36","author":"Ahuja","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.107989_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1330","article-title":"Neurodegenerative diseases and oxidative stress","volume":"3","author":"Barnham","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.107989_bib3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nrc2522","article-title":"Ageing, oxidative stress and cancer: paradigms in parallax","volume":"8","author":"Benz","year":"2008","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.neuropharm.2020.107989_bib4","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1039\/c3cc38386e","article-title":"An asymmetric approach toward chiral multicyclic spirooxindoles from isothiocyanato oxindoles and unsaturated pyrazolones by a chiral tertiary amine thiourea catalyst","volume":"49","author":"Chen","year":"2013","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.neuropharm.2020.107989_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1021\/acs.jmedchem.8b01527","article-title":"Optimization of vinyl sulfone derivatives as potent nuclear factor erythroid 2-related factor 2 (Nrf2) activators for Parkinson's disease therapy","volume":"62","author":"Choi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib6","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.bmcl.2005.03.031","article-title":"Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action","volume":"15","author":"Couch","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2020.107989_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/13543780802716501","article-title":"The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease","volume":"13","author":"Cuadrado","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2020.107989_bib8","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/acs.jmedchem.6b00228","article-title":"Monoacidic inhibitors of the kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery","volume":"59","author":"Davies","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.107989_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/tx100389r","article-title":"Modification of keap1 cysteine residues by sulforaphane","volume":"24","author":"Hu","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.107989_bib11","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1074\/jbc.275.21.16023","article-title":"Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages","volume":"275","author":"Ishii","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","article-title":"An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements","volume":"236","author":"Itoh","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2020.107989_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.neuropharm.2020.107989_bib14","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1021\/jm5000529","article-title":"Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis","volume":"57","author":"Jiang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib15","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/acs.jmedchem.5b00185","article-title":"Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar keap1-nrf2 protein-protein interaction inhibitor","volume":"58","author":"Jiang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib16","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1021\/acs.jmedchem.6b00586","article-title":"Discovery and development of kelch-like ECH-associated protein 1. Nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction inhibitors: achievements, challenges, and future directions","volume":"59","author":"Jiang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1427.036","article-title":"The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration","volume":"1147","author":"Johnson","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2020.107989_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.neuropharm.2016.10.029","article-title":"Agmatine ameliorates type 2 diabetes induced-Alzheimer's disease-like alterations in high-fat diet-fed mice via reactivation of blunted insulin signalling","volume":"113","author":"Kang","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107989_bib19","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1016\/j.tetlet.2016.06.102","article-title":"Synthesis of tetrahydropyranyl diarylheptanoids from Dioscorea villosa","volume":"57","author":"Kantee","year":"2016","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.neuropharm.2020.107989_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","article-title":"Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway","volume":"47","author":"Kensler","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.107989_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1749-6632.2011.06092.x","article-title":"Regulation of the Keap1\/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modification","volume":"1229","author":"Keum","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2020.107989_bib22","doi-asserted-by":"crossref","first-page":"11624","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2020.107989_bib23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.107989_bib24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/bph.12973","article-title":"A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model","volume":"172","author":"Lee","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.107989_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2174\/0929867013372896","article-title":"Oxidative stress and antioxidants in exercise","volume":"8","author":"Leeuwenburgh","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.107989_bib27","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1021\/acs.jmedchem.6b00775","article-title":"Design, synthesis, and initial evaluation of affinity-based small-molecule probes for fluorescent visualization and specific detection of Keap1","volume":"59","author":"Lu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/pr.110.004333","article-title":"Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2","volume":"64","author":"Ma","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2020.107989_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/med.21257","article-title":"Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents","volume":"32","author":"Magesh","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2020.107989_bib30","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1016\/j.bmc.2013.04.019","article-title":"Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism","volume":"21","author":"Marcotte","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib31","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1016\/j.tetlet.2012.05.148","article-title":"Straightforward copper-catalyzed synthesis of pyrrolopyrazoles from halogenated pyrazolecarbaldehydes","volume":"53","author":"Nayak","year":"2012","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.neuropharm.2020.107989_bib32","doi-asserted-by":"crossref","first-page":"15989","DOI":"10.3390\/molecules200915989","article-title":"Antioxidant and anti-inflammatory activities of a natural compound, shizukahenriol, through Nrf2 activation","volume":"20","author":"Park","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2020.107989_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.107989_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","article-title":"Expression of Nrf2 in neurodegenerative diseases","volume":"66","author":"Ramsey","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107989_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/glia.20947","article-title":"A. Cuadrado, Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease","volume":"58","author":"Rojo","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2020.107989_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neuropharm.2013.11.004","article-title":"NRF2-regulation in brain health and disease: implication of cerebral inflammation","volume":"79","author":"Sandberg","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107989_bib37","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1021\/acschemneuro.7b00100","article-title":"Targeting the nrf2\/amyloid-beta liaison in alzheimer's disease: a rational approach","volume":"8","author":"Simoni","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.107989_bib38","doi-asserted-by":"crossref","first-page":"15550","DOI":"10.1073\/pnas.1416940111","article-title":"Sulforaphane treatment of autism spectrum disorder (ASD)","volume":"111","author":"Singh","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.107989_bib39","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrc3278","article-title":"NRF2 and cancer: the good, the bad and the importance of context","volume":"12","author":"Sporn","year":"2012","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.neuropharm.2020.107989_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1039\/C3MD00240C","article-title":"Novel protein\u2013protein interaction inhibitor of Nrf2\u2013Keap1 discovered by structure-based virtual screening","volume":"5","author":"Sun","year":"2014","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.neuropharm.2020.107989_bib41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0361-9230(00)00427-5","article-title":"Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents","volume":"54","author":"Tariq","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2020.107989_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.107989_bib43","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.freeradbiomed.2008.09.001","article-title":"Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?","volume":"45","author":"de Vries","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2020.107989_bib44","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1073\/pnas.0307301101","article-title":"Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers","volume":"101","author":"Wakabayashi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.107989_bib45","doi-asserted-by":"crossref","first-page":"33627","DOI":"10.1074\/jbc.274.47.33627","article-title":"Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2","volume":"274","author":"Wild","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm401788m","article-title":"Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy","volume":"57","author":"Woo","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.107989_bib47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1021\/jm4017174","article-title":"Rapid identification of Keap1-Nrf2 small-molecule inhibitors through structure-based virtual screening and hit-based substructure search","volume":"57","author":"Zhuang","year":"2014","journal-title":"J. Med. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:59:11Z","timestamp":1758437951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820300551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":47,"alternative-id":["S0028390820300551"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107989","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107989"}}